Abstract
Meclizine is a well-tolerated drug routinely used as an anti-histamine agent in the management of disequilibrium. Recently, meclizine has been assessed for its neuroprotective properties in ischemic stroke and Huntington disease models. We found that meclizine protected against 6-hydroxydopamine-induced apoptosis and cell death in both SH-SY5Y cells and rat primary cortical cultures. Meclizine increases the level of 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3), which activates phosphofructokinase, a rate-determining enzyme of glycolysis. This protection is therefore mediated by meclizine's ability to enhance glycolysis and increase mitochondrial hyperpolarization. Meclizine represents an interesting candidate for further investigation to re-purpose for its potential to be neuroprotective in Parkinson disease.
| Original language | English |
|---|---|
| Article number | 25344 |
| Journal | Scientific Reports |
| Volume | 6 |
| DOIs | |
| Publication status | Published - May 5 2016 |
Fingerprint
ASJC Scopus subject areas
- General
Cite this
Meclizine-induced enhanced glycolysis is neuroprotective in Parkinson disease cell models. / Hong, Chien Tai; Chau, Kai Yin; Schapira, Anthony H V.
In: Scientific Reports, Vol. 6, 25344, 05.05.2016.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Meclizine-induced enhanced glycolysis is neuroprotective in Parkinson disease cell models
AU - Hong, Chien Tai
AU - Chau, Kai Yin
AU - Schapira, Anthony H V
PY - 2016/5/5
Y1 - 2016/5/5
N2 - Meclizine is a well-tolerated drug routinely used as an anti-histamine agent in the management of disequilibrium. Recently, meclizine has been assessed for its neuroprotective properties in ischemic stroke and Huntington disease models. We found that meclizine protected against 6-hydroxydopamine-induced apoptosis and cell death in both SH-SY5Y cells and rat primary cortical cultures. Meclizine increases the level of 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3), which activates phosphofructokinase, a rate-determining enzyme of glycolysis. This protection is therefore mediated by meclizine's ability to enhance glycolysis and increase mitochondrial hyperpolarization. Meclizine represents an interesting candidate for further investigation to re-purpose for its potential to be neuroprotective in Parkinson disease.
AB - Meclizine is a well-tolerated drug routinely used as an anti-histamine agent in the management of disequilibrium. Recently, meclizine has been assessed for its neuroprotective properties in ischemic stroke and Huntington disease models. We found that meclizine protected against 6-hydroxydopamine-induced apoptosis and cell death in both SH-SY5Y cells and rat primary cortical cultures. Meclizine increases the level of 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3), which activates phosphofructokinase, a rate-determining enzyme of glycolysis. This protection is therefore mediated by meclizine's ability to enhance glycolysis and increase mitochondrial hyperpolarization. Meclizine represents an interesting candidate for further investigation to re-purpose for its potential to be neuroprotective in Parkinson disease.
UR - http://www.scopus.com/inward/record.url?scp=84966365384&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84966365384&partnerID=8YFLogxK
U2 - 10.1038/srep25344
DO - 10.1038/srep25344
M3 - Article
AN - SCOPUS:84966365384
VL - 6
JO - Scientific Reports
JF - Scientific Reports
SN - 2045-2322
M1 - 25344
ER -